Bladder Cancer Treatment Drugs Market

Bladder Cancer Treatment Drugs Market Outlook (2023 to 2033)

The Global Bladder Cancer Treatment Drugs Market recorded a valuation of US$ 3.04 billion in 2022 and is expected to jump to US$ 14.8 billion by the end of 2033, expanding rapidly at a CAGR of 15.6% over the next ten years. According to this new study by Persistence Market Research, North America is the leading regional market and accounted for a market share of 46.7% in 2022.

There are two types of bladder cancers. One type is where only the bladder lining is impacted by non-muscle invasive bladder cancer. It does not penetrate the innermost layer of the bladder or the deeper layer of the bladder's muscles. This illness is known as 'superficial bladder cancer'. Muscle-invasive bladder cancer is the second type where the cancerous cells have migrated into or through the muscle layer of the bladder wall. There are numerous treatment options available, including chemotherapy, surgery, and radiotherapy.

• Sales of bladder cancer treatment drugs accounted for 1.4% share of the global oncology drugs market in 2022.

Cancer cells may stop reproducing and developing when exposed to chemotherapy (cytotoxic) drugs, which may also result in tumors becoming smaller. Drugs used to kill cancer cells are known as cytotoxic medicines or cytostatic (also known as cytotoxic chemotherapy). With the advancement of pharmacological therapy, the importance of cytotoxic medications in cancer treatment has marginally decreased.

Cancer immunotherapy, commonly referred to as immuno-oncology, is a type of cancer treatment that takes advantage of the immune system's capacity to stop, manage, and eradicate cancer. Targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants are a few of the different forms it might take. When components from live organisms are employed to treat the condition, it is known as a biological treatment.

Targeted therapy is a sort of treatment that targets particular cancer cell types with medications or other substances while causing the least amount of damage to healthy cells. Some proteins, enzymes, or other substances involved in the growth and spread of cancer cells are blocked by several targeted therapies.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Sales Analysis of Bladder Cancer Treatment Drugs (2012 to 2022) Vs. Market Outlook (2023 to 2033)

“Increased Financing for Research and Growing Clinical Studies for Cancer”

The global market expanded at a CAGR of 16.6% from 2012 to 2022 mainly due to a boost in cancer research funding.

As a result of increased financing for cancer research, the quality of life for cancer patients has improved significantly and patient survival rates have significantly risen.

The National Cancer Institute (NCI) offers funding for research projects in fields where the commercial sector lacks interest, including ground-breaking basic research and projects on cancer screening, prevention, and rare malignancies.

The National Institutes for Health (NIH) in the United States is the largest public supporter of biomedical research in the entire globe. The United States is now a global leader in the development of cancer medicines and diagnostic techniques because of NIH-funded research that has spurred discoveries that businesses rely on to bring novel cancer medications to market.

• The Consolidated Appropriations Act of 2022 provided the National Cancer Institute (NCI) with US$ 6.9 billion, an increase of US$ 353 million over FY 2021. In April 2016, the U.S. government gave the National Cancer Institute (NCI) US$5.2 billion, a 5.3% increase from the prior year.

Clinical studies are carried out by the NCI on cancer patients whose prognosis requires several diagnoses. Companies are encouraged to perform more research on cancer diagnosis and therapy when there is more funding for the same.

• As per the CDC 2020 report, Cancer was the second-highest cause of mortality in the U.S. in 2020, behind heart disease. In 2020, 602,350 people died from cancer, including 284,619 women and 317,731 men. Cancer deaths per 100,000 persons declined from 196.5 in 2001 to 144.1 in 2020, a 27% decrease. A majority of cancer-related fatalities occur in low- and middle-income nations.

One-third of all fatalities are attributable to the primary behavioral and dietary risk factors for death: high body mass index, inadequate intake of fruits and vegetables, lack of physical exercise, and excessive tobacco and alcohol consumption.

Cancer mortality rates are continuing to decrease as a result of screening for some cancers, including breast, cervical, colon, prostate, rectal, and more recently, lung cancer, as well as the availability of combination therapies for many cancers and the use of chemotherapy after surgery for breast and colon cancer.

Owing to the factors mentioned above, the global bladder cancer treatment drugs market is forecasted to surge ahead at a CAGR of 15.6% during the forecast period (2023 to 2033).

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

Get a Customized Version

What are the Key Opportunities for Bladder Cancer Drug Manufacturers?

“Switching to Molecularly Targeted Medications or Immunotherapies”

The idea of switching to molecularly targeted medications or immunotherapies instead of conventional chemotherapy, which has historically been the basis of first-line treatment for advanced malignancies, has many appeals because they promise improved efficacy and enhanced quality of life.

• Although early leaders Bristol-Myers Squibb, Merck, and Roche have the most well-established immunotherapy drug portfolios, AstraZeneca and Ferring B.V. have remarkable portfolios of early checkpoint-based immunotherapy approaches. A majority of these pharmaceuticals are expected to generate sell-side income of roughly US$ 1 billion in a few years.

In the next ten years, some estimates claim that the market for immunotherapy as a whole might represent 30% to 40% of the market for oncology medicines. This prediction becomes more realistic with each regulatory permission that major businesses in this sector acquire.

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

How is Market Growth Being Affected to Some Extent?

“High Cost for Drug Development and Lack of Availability of Cancer Medications in Underdeveloped & Emerging Nations”

Since it takes a long time and costs a lot of money, drug development is not easy. As it typically takes 10 years from synthesis to approval and 88% of medications are refused, studying the drug to ascertain its efficacy and safety comes at a significant cost. Drug duplication is another obstacle to the market.

• The dearth of innovation in new cancer medications in 2014 resulted in 74% of the new medications created by nine of the top 10 pharmaceutical companies being identical to those created by their rivals.
• According to a PharmacoEconomics study article in 2019, estimates of the total average capitalized pre-market R&D expenses ranged widely, from US$ 161 million to US$ 4.54 billion (2019). Anti-cancer medication had the highest therapeutic area-specific projections ($944 million to $4.54 billion).

The fact that a majority of important cancer medications are not available in underdeveloped and emerging nations is one of the main issues restricting the growth of the worldwide market for pharmaceuticals to treat bladder cancer.

• According to a publication by NIH in 2020 on Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe, the United States, Germany, and the United Kingdom are the only countries where more than 40 of the 55 cancer medications that were originally approved between 2012 and 2016 are available.

A majority of the world's countries lack access to pharmaceuticals because their makers either failed to obtain regulatory permission, their approval was delayed or denied, or their manufacturers were waiting for the outcome of reimbursement negotiations before releasing the drug there. Most new pharmaceutical markets allegedly have less than 20% of cancer medications available.

• According to data published by NIH in 2021 on Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries, in low- to middle-income countries, 32% of EML medications are only available at full price, while 5.2% are completely unavailable. At 57.7% and 8.3%, respectively, the similar numbers for low-income countries (LICs) are far worse.

Several factors, including a deficient healthcare system, inadequate infrastructure, and additional obstacles such as fragmented diagnostic environments, a shortage of or unequal distribution of healthcare workers, and numerous logistical and financial challenges such as high costs, lack of quality assurance, frequent stock-outs, and difficult regulatory pathways, cause this.

• According to data published by NIH in November 2022 on Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa less than 50% of the cancer medications listed on the WHO EML are available to patients in LMICs, which make up more than 45% of the global population.

Zaid Sheikh
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert

I'm Available

Country-wise Insights

Why is the United States a Large Market for Bladder Cancer Treatment Drugs?

“High Spending on Cancer-Related Medical Treatment”

The United States held 43% share of the global market in 2022. Rising cancer treatment spending is the chief driver for this market.

• Spending on cancer-related medical treatment in the United States was US$ 183 billion in 2015; by 2030, that amount is predicted to increase to US $246 billion, a 34% increase.
• In 2019, U.S. patients paid an estimated US$ 16.2 billion out-of-pocket for cancer care and lost close to US$ 5 billion in productivity, according to a yearly report by researchers at the CDC, the National Cancer Institute, the American Cancer Society, and the North American Association of Central Cancer Registries.

How is the United Kingdom Market for Bladder Cancer Treatment Drugs Evolving?

“Expansion of Cancer Therapy Options”

The United Kingdom accounted for 4.4% share of the global market for bladder cancer treatment drugs in 2022.

Market growth is attributed to the expansion of cancer therapy options. There are numerous cutting-edge cancer treatments available all over the world. In addition, the drive for innovation in cancer treatments is being monitored by academic institutions, biopharmaceutical firms, and healthcare system stakeholders.

• The EMA (European Medicines Agency) approved twice as many novel Bladder Cancer Treatment Treatments (NAS) in 2019 as it did in 2020. 64 new drugs for the treatment of bladder cancer have been introduced globally in the last five years, bringing the 20-year total to 161. There were 37 new cancer medications introduced in the U.K. alone.

Category-wise Insights

Which Type of Cancer Accounts for High Demand for These Drugs?

“Non-Muscle-Invasive Bladder Cancer Accounts for Huge Market Share”

Drugs used for non-muscle-invasive bladder cancer generated revenue worth US$ 2.15 billion in 2022, with the segment projected to expand at a CAGR of 14.8% during the forecast period owing to the high rates of recurrence and risk of progression.

According to a 2019 article from the World Journal of Oncology, 70% to 75% of all cancers are non-muscle-invasive. This is the initial type before progressing to muscle invasion. Healthcare professionals focus on destroying cancer before it penetrates the muscles; hence the higher adoption.

Will Low-Grade Bladder Cancer Continue Accounting for High Demand for Drug Treatment?

“Lower Risk of Recurrence after Drug-related Treatment”

Low-grade bladder cancer accounted for a market revenue share of 69.8% in 2022. Low-grade bladder cancers are mostly on the bladder surface, rarely spread or metastasize, and also have a lower risk of recurrence after treatment. When tumors have been surgically removed, drug cleansing of the bladder may lower the likelihood of cancer returning.

Competitive Landscape

The global market is consolidated with a limited number of key players. Considering the competition from local players, key market players in the industry are focusing on acquiring such competitors to reach a large customer base, along with expanding into newer markets. Manufacturers are also coming up with innovative products, most of which are currently in the pipeline.

• On 26 January 2021, Hikma confirmed the acquisition of GSK’s interests in entities and assets comprising GSK’s pharmaceutical and consumer commercialization and manufacturing business in Egypt and the pharmaceutical division of GSK’s business in Tunisia.
• On 5 July 2022, AstraZeneca announced an agreement for the acquisition of TeneoTwo and its clinical-stage T-cell engager, thereby strengthening its haematological cancer pipeline.

Bladder Cancer Treatment Drugs Industry Report Scope

Bladder Cancer Treatment Drugs Industry Research Segmentation

By Cancer Type:

• Non-Muscle-Invasive Bladder Cancer
• Muscle-Invasive Bladder Cancer

By Cancer Grade:

• Low-Grade Bladder Cancer
• High-Grade Bladder Cancer

By Drug Type:

• Immunotherapy
  • Bacillus Calmette-Guerin
  • Avelumab
  • Nivolumab
  • Pembrolizumab
  • Others
• Chemotherapy
  • Mitomycin C
  • Docetaxel
  • Paclitaxel
  • Cisplatin
  • Others
• Targeted Therapy
  • Erdafitinib
  • Enfortumab vedotin-ejfv
  • Sacituzumab govitecan
  • Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)